Veradermics, Inc. (MANE)
102.23
+3.77
(+3.83%)
USD |
NYSE |
Aug 25, 16:00
102.23
0.00 (0.00%)
After-Hours: 17:57
Veradermics Enterprise Value : 3.294B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 3.294B |
| August 21, 2026 | 3.476B |
| August 20, 2026 | 3.581B |
| August 19, 2026 | 3.828B |
| August 18, 2026 | 3.831B |
| August 17, 2026 | 3.702B |
| August 14, 2026 | 3.890B |
| August 13, 2026 | 3.818B |
| August 12, 2026 | 3.737B |
| August 11, 2026 | 3.732B |
| August 10, 2026 | 3.808B |
| August 07, 2026 | 3.960B |
| August 06, 2026 | 3.720B |
| August 05, 2026 | 3.832B |
| August 04, 2026 | 3.663B |
| August 03, 2026 | 3.438B |
| July 31, 2026 | 3.567B |
| July 30, 2026 | 3.552B |
| July 29, 2026 | 3.683B |
| July 28, 2026 | 3.841B |
| July 27, 2026 | 3.836B |
| July 24, 2026 | 3.756B |
| July 23, 2026 | 4.021B |
| July 22, 2026 | 3.770B |
| July 21, 2026 | 3.755B |
| Date | Value |
|---|---|
| July 20, 2026 | 3.611B |
| July 17, 2026 | 3.831B |
| July 16, 2026 | 3.602B |
| July 15, 2026 | 4.349B |
| July 14, 2026 | 3.783B |
| July 13, 2026 | 3.784B |
| July 10, 2026 | 4.177B |
| July 09, 2026 | 4.399B |
| July 08, 2026 | 4.121B |
| July 07, 2026 | 4.060B |
| July 06, 2026 | 4.281B |
| July 02, 2026 | 4.601B |
| July 01, 2026 | 4.548B |
| June 30, 2026 | 4.317B |
| June 29, 2026 | 4.224B |
| June 26, 2026 | 4.347B |
| June 25, 2026 | 4.067B |
| June 24, 2026 | 3.989B |
| June 23, 2026 | 3.478B |
| June 22, 2026 | 3.447B |
| June 18, 2026 | 3.114B |
| June 17, 2026 | 3.040B |
| June 16, 2026 | 3.005B |
| June 15, 2026 | 3.204B |
| June 12, 2026 | 3.196B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.220T |
| EyePoint, Inc. | 255.76M |
| Elanco Animal Health, Inc. | 15.59B |
| Tarsus Pharmaceuticals, Inc. | 2.790B |
| Amylyx Pharmaceuticals, Inc. | 4.003B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.50M |
| Total Expenses (Quarterly) | 23.50M |
| EPS Diluted (Quarterly) | -0.5625 |
| Earnings Yield | -2.55% |
| Normalized Earnings Yield | -2.547 |